Dr. Hassan Hatoum, MD

Dr. Hatoum practices at Ou Medical Center-The Children's Ho - Rad CT - HOPD in Oklahoma City, Oklahoma.

Dr. Hatoum's NPI, 1902137540, was assigned on January 21, 2010. Dr. Hatoum holds Oklahoma license 31656.

Dr. Hatoum's primary practice is Ou Medical Center-the Children's Ho - Rad CT - HOPD, at 1200 Childrens Ave, Oklahoma City, OK 73104.

Dr. Hatoum's primary practice is Ou Medical Center-The Children's Ho - Rad CT - HOPD in Oklahoma City, Oklahoma. Dr. Hatoum is also affiliated with OU Health University of Oklahoma Medical Center. The medical group on file is OU Health. Dmand AI also links Dr. Hatoum to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hatoum practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Hatoum's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Hatoum is licensed in Oklahoma.

CMS data shows 513 Medicare services from Dr. Hatoum across 5 procedure codes in 2024, for 172 Medicare patients. Medicare paid $45,478 for them.

CMS counts 172 Medicare patients who saw Dr. Hatoum in 2024. The largest group is 65 to 74, with 87 patients. 75% of them have high blood pressure, and 66% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.48, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hatoum's median patient age at 71, with 47% women.

In 2024, Dr. Hatoum wrote 926 Medicare Part D claims for 150 patients. 73% of them were for generic drugs. CMS names the drug for 739 of them, across 29 drugs with 11 or more claims each, at $1,567,415 in total drug cost. In 2023, CMS named 952 claims across 31 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 77 out of 100 for Dr. Hatoum for performance year 2024, reported as part of a group. Dr. Hatoum accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 12 papers to Dr. Hatoum, published from 2011 to 2021. 2014 was the busiest year, with 2. The most frequent topics are Pancreatic Neoplasms, Adenocarcinoma and Neuroendocrine Tumors. Dr. Hatoum has published most often in Oncologist. Dr. Hatoum's most frequent co-authors are Sarbajit Mukherjee, Hussein Assi, MD and Grace K. Dy, MD.

Dmand AI links Dr. Hatoum to 10 clinical trials, 5 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Anal Canal Carcinoma, Cholangiocarcinoma and Colonic Neoplasms. National Cancer Institute (NCI) sponsors the most, 6.

CMS Open Payments shows 108 general payments to Dr. Hatoum from 22 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 32% of the total. Bristol-Myers Squibb Company paid the most, $6,620.